human ace2

MLN-4760 是选择性的人ACE2抑制剂，IC50=0.44 nM，对人ACE2的选择性是其他相关蛋白的 5000 多倍，包括人睾丸 ACE (IC50，>100 μM) 和牛 carboxypeptidase A (IC50，27 μM)。

SSAA09E2 是一种新型的SARS-CoV 复制抑制剂，通过阻断SARS-S 与SARS-CoV 受体血管紧张素转换酶-2 的早期相互作用发挥作用。

SARS-CoV-2-IN-109 (compound 50) 是一种针对 SARS-CoV 的抑制剂，具有体内对抗感染的活性。它通过影响 SARS-CoV-2 Spike 受体结合域 (RBD) 与人类受体血管紧张素转换酶 2 (ACE2) 的相互作用来发挥作用，EC50 为 26.5 μM，并阻止 SARS-CoV-2 进入 VeroE6 细胞，ECS50 为 17.0 μM。此外，SARS-CoV-2-IN-109 对 VeroE6 细胞的 CC50 大于 100 μM。

CK2-IN-15 (Compound Biv5) 是一种有效且具有选择性的二价蛋白激酶CK2抑制剂，IC50值为51 pM。它在HEK-ACE2-TMPRSS2和Vero细胞中显著降低了SARS-CoV-2的复制，在人类鼻上皮细胞的体外模型中也显示出抑制病毒复制的效果。CK2-IN-15 有潜力用于研究与 β 冠状病毒感染相关的疾病。

Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach for SARS-CoV-2 treatment[1]. [1]. Chunyan Wang, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 May 4;11(1):2251.

Human ACE2 receptor-derived 23-amino acid peptide. Binds receptor binding domain (RBD) of insect-derived SARS-CoV-2 spike protein (KD = 1.3 μM for N-terminal biotinylated, insect-derived spike protein RBD; see Zhang et al preprint publication). Please note - unpublished, in-house data suggests approximately 75-fold lower affinity for insect-derived SARS-CoV-2 RBD than reported by Zhang et al.

Fluorescently labelled peptide derived from human ACE2 (SBP1, Cat. No. 7233). Composed of SBP1 conjugated to FITC (Fluorescein-5-isothiocyanate; Cat. No. 5440). SBP1 binds receptor binding domain (RBD) of insect-derived SARS-CoV-2 spike protein (KD = 1.3 μM for N-terminal biotinylated, insect-derived spike protein RBD; see Zhang et al preprint publication). Please note - unpublished, in-house data suggests SBP1 has approximately 75-fold lower affinity for insect-derived SARS-CoV-2 RBD than reported by Zhang et al.

CMX990是SARS-CoV-2 3CL蛋白酶抑制剂。在人支气管上皮细胞(HBECs)和HeLa-ACE2细胞中，其抑制SARS-CoV-2的EC90s分别为9.6 nM和101 nM。CMX990具有良好的ADME和药代动力学特性。

Canvircept 是一种重组融合蛋白，由血管紧张素转换酶 2（ACE2）与人 IgG1Fc 融合组成。